Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma

Published:2018-07 Issue: Volume:82 Page:83-90
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Ferrarotto Renata^ORCID,William William N.,Tseng Jennifer E.,Marur Shanthi,Shin Dong M.,Murphy Barbara,Cohen Ezra E.W.,Thomas Christopher Y.,Willey Richard,Cosaert Jan,Harun Nusrat,Jack Lee J.^ORCID,Wistuba Ignacio W.,Haddad Robert I.,Glisson Bonnie S.

Funder

Merck

BMS

Pfizer

AstraZeneca

Genentech

Eli Lilly and Company

UTMDACC Head and Neck Cancer SPORE

MDACC Support

Conquer Cancer Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference34 articles.

1. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells;Jameson;Mol Cancer Ther,2011

3. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma;Chung;Head Neck,2011

4. Structure and function of the type 1 insulin-like growth factor receptor;Adams;Cell Mol Life Sci.,2000

5. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis;Wang;Curr Cancer Drug Targets,2002

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment;Cancers;2023-08-24

2. The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy;Frontiers in Bioscience-Landmark;2023-08-11

3. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

4. Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review;Cancer Reports;2023-04-12

5. Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis;Cancers;2022-09-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3